Drug Helps Brain Tumor Patients Live Longer

People who receive high doses of the chemotherapy drug methotrexate to treat a certain type of brain tumor appear to live longer than people receiving other treatments, according to new research.

Share:

Total shares:

FULL STORY

People who receive high doses of the chemotherapy drug methotrexate to treat a certain type of brain tumor appear to live longer than people receiving other treatments, according to research published in the January 29, 2008, issue of Neurology®, the medical journal of the American Academy of Neurology.

"Our findings show high-dose methotrexate alone or in combination with other chemotherapy drugs is the most effective treatment available for primary central nervous system lymphoma (PCNSL)" said study author Tracy Batchelor, MD, with the Massachusetts General Hospital Cancer Center in Boston. PCNSL can be a potentially curable brain tumor or one in which there can be a long remission.

The research involved 25 adults with newly diagnosed PCNSL who received a high dose of methotrexate every two weeks for four months or until there were no signs of the brain tumor. The participants were then followed for a minimum of 6.5 years.

The article found 52 percent of the participants achieved complete remission and 40 percent of these patients have not relapsed after an average of seven years. The average survival rate of all participants who received methotrexate was 4.5 years. In contrast, the average survival rate for patients who receive radiation therapy for this type of brain tumor is one year.

"Our findings support the role of methotrexate as a critical chemotherapy drug in the treatment of this type of brain tumor," said Batchelor. "Moreover, it appears some people may achieve a long remission through the methotrexate alone."

Batchelor says further studies are needed to identify the optimal methotrexate dose and combination therapy that will produce the most effective results with minimum side effects.

The study was supported by the National Cancer Institute and conducted in the New Approaches to Brain Tumor Therapy (NABTT) consortium.

July 31, 2015  School is just around the corner, which means backpacks and packed lunches await your children. One expert offers tips for parents to promote healthy dental habits while away from ... read more

July 29, 2015  By blocking the expression of a certain gene in patients, researchers have contributed to the demonstration of great decreases in the concentration of triglycerides in their ... read more

July 29, 2015  Viewing aquarium displays led to noticeable reductions in blood pressure and heart rate, a research team found in the first study of its kind. They also noted that higher numbers of fish helped to ... read more

Dec. 14, 2012  Researchers have identified over 125 genetic components in a chemotherapy-resistant, brain tumor-derived cell line, which could offer new hope for drug treatment to destroy the cancer cells. The ... read more

Aug. 31, 2011  New research suggests brain tumor patients who take the seizure drug valproic acid on top of standard treatment may live longer than people who take other kinds of epilepsy medications to control ... read more

Sep. 22, 2010  Scientists are reporting the development and successful initial testing of a new form of methotrexate -- the mainstay anticancer drug -- designed to be given as nose drops rather than injected. It ... read more